Enhanced Access to Affordable Medicines Act of 2022
This bill specifies that the Food and Drug Administration may approve generic drugs with different labels than the brand-name versions if, among other requirements, the brand-name drug is subject to an active patent or exclusivity period and a revised label for the brand-name drug is approved within 90 days (rather than 60 days) of the expiration of the patent or exclusivity period.
| Action Date | Type | Text | Source |
|---|---|---|---|
| 2022-03-09 | Committee | Referred to the Subcommittee on Health. | House committee actions |
| 2022-03-08 | IntroReferral | Referred to the House Committee on Energy and Commerce. | House floor actions |
| 2022-03-08 | IntroReferral | Introduced in House | Library of Congress |